New Rapid Test Detects Influenza A, B, and COVID-19 in Single Assay
The CLIA-waived immunoassay delivers results in as fast as 10 minutes and is designed for physician offices, urgent care centers, and decentralized hospital labs.
The CLIA-waived immunoassay delivers results in as fast as 10 minutes and is designed for physician offices, urgent care centers, and decentralized hospital labs.
SEKISUI Diagnostics has launched the Metrix COVID/Flu Test, a rapid molecular diagnostic for SARS-CoV-2 and influenza.
Detact Diagnostics has received $5.9M in grants from the Bill & Melinda Gates Foundation to develop point-of-care diagnostic tests.
An international team thinks they have the solution to identify infection in a wound: a device run from a smartphone or tablet app.
The FDA has authorized Cepheid's Xpert HCV test and GeneXpert Xpress System, the first point-of-care HCV test for certified settings.
Sekisui formalized an exclusive distribution agreement with Aptitude Medical Systems to sell the Aptitude Metrix COVID Test in the U.S.Â